Ignite Creation Date:
2024-05-05 @ 9:42 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00008372
Status:
COMPLETED
Last Update Posted:
2011-10-20
First Post:
2001-01-06
Brief Title:
Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer
Sponsor:
City of Hope Medical Center
Organization:
City of Hope Medical Center
Study Overview
Official Title:
Phase II Trial Of CQS NSC 339004 In Platinum-Refractory Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of chloroquinoxaline sulfonamide in treating patients who have small cell lung cancer that has not responded to platinum-based chemotherapy
PURPOSE Phase II trial to study the effectiveness of chloroquinoxaline sulfonamide in treating patients who have small cell lung cancer that has not responded to platinum-based chemotherapy
Detailed Description:
OBJECTIVES I Determine the efficacy of chloroquinoxaline sulfonamide in patients with platinum-refractory small cell lung cancer II Determine the toxic effects of this drug in these patients
OUTLINE Patients receive chloroquinoxaline sulfonamide IV over 1 hour once a week for 4 weeks Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity Patients are followed until death
PROJECTED ACCRUAL A total of 12-38 patients will be accrued for this study within 12-18 months
OUTLINE Patients receive chloroquinoxaline sulfonamide IV over 1 hour once a week for 4 weeks Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity Patients are followed until death
PROJECTED ACCRUAL A total of 12-38 patients will be accrued for this study within 12-18 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA033572 | NIH | None | None |
| CHNMC-PHII-26 | None | None | None |
| NCI-57 | None | None | None |
| CDR0000068401 | REGISTRY | NCI PDQ | httpsreporternihgovquickSearchP30CA033572 |